BioMarin Pharma (BMRN) Tops Q4 EPS by 29c ; Offers Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.49, $0.29 better than the analyst estimate of $0.20. Revenue for the quarter came in at $646.2 million versus the consensus estimate of $639.26 million.

GUIDANCE:

BioMarin Pharma sees FY2024 EPS of $2.60-$2.80, versus the consensus of $2.83. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.82 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Wall Street scrambles to lift Micron price targets ahead of earnings
• Hyperscale Data launches $300M at-the-market stock offering